These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene. Klutz K; Willhauck MJ; Dohmen C; Wunderlich N; Knoop K; Zach C; Senekowitsch-Schmidtke R; Gildehaus FJ; Ziegler S; Fürst S; Göke B; Wagner E; Ogris M; Spitzweg C Hum Gene Ther; 2011 Dec; 22(12):1563-74. PubMed ID: 21851208 [TBL] [Abstract][Full Text] [Related]
4. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy. Mitrofanova E; Unfer R; Vahanian N; Link C Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480 [TBL] [Abstract][Full Text] [Related]
5. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Spitzweg C; O'Connor MK; Bergert ER; Tindall DJ; Young CY; Morris JC Cancer Res; 2000 Nov; 60(22):6526-30. PubMed ID: 11103823 [TBL] [Abstract][Full Text] [Related]
6. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Kakinuma H; Bergert ER; Spitzweg C; Cheville JC; Lieber MM; Morris JC Cancer Res; 2003 Nov; 63(22):7840-4. PubMed ID: 14633711 [TBL] [Abstract][Full Text] [Related]
7. Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats. Faivre J; Clerc J; Gérolami R; Hervé J; Longuet M; Liu B; Roux J; Moal F; Perricaudet M; Bréchot C Cancer Res; 2004 Nov; 64(21):8045-51. PubMed ID: 15520214 [TBL] [Abstract][Full Text] [Related]
8. Genetically targeted radiotherapy of head and neck squamous cell carcinoma using the sodium-iodide symporter (NIS). Gaut AW; Niu G; Krager KJ; Graham MM; Trask DK; Domann FE Head Neck; 2004 Mar; 26(3):265-71. PubMed ID: 14999802 [TBL] [Abstract][Full Text] [Related]
9. In vivo sodium iodide symporter gene therapy of prostate cancer. Spitzweg C; Dietz AB; O'Connor MK; Bergert ER; Tindall DJ; Young CY; Morris JC Gene Ther; 2001 Oct; 8(20):1524-31. PubMed ID: 11704812 [TBL] [Abstract][Full Text] [Related]
11. AFP promoter enhancer increased specific expression of the human sodium iodide symporter (hNIS) for targeted radioiodine therapy of hepatocellular carcinoma. Ma XJ; Huang R; Kuang AR Cancer Invest; 2009 Jul; 27(6):673-81. PubMed ID: 19241193 [TBL] [Abstract][Full Text] [Related]
12. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells. Schipper ML; Weber A; Béhé M; Göke R; Joba W; Schmidt H; Bert T; Simon B; Arnold R; Heufelder AE; Behr TM Cancer Res; 2003 Mar; 63(6):1333-8. PubMed ID: 12649195 [TBL] [Abstract][Full Text] [Related]
13. In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas. Cho JY; Shen DH; Yang W; Williams B; Buckwalter TL; La Perle KM; Hinkle G; Pozderac R; Kloos R; Nagaraja HN; Barth RF; Jhiang SM Gene Ther; 2002 Sep; 9(17):1139-45. PubMed ID: 12170377 [TBL] [Abstract][Full Text] [Related]
14. Rat sodium iodide symporter for radioiodide therapy of cancer. Mitrofanova E; Unfer R; Vahanian N; Daniels W; Roberson E; Seregina T; Seth P; Link C Clin Cancer Res; 2004 Oct; 10(20):6969-76. PubMed ID: 15501976 [TBL] [Abstract][Full Text] [Related]
15. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Dwyer RM; Bergert ER; O'connor MK; Gendler SJ; Morris JC Clin Cancer Res; 2005 Feb; 11(4):1483-9. PubMed ID: 15746050 [TBL] [Abstract][Full Text] [Related]
16. Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: effect on clonogenicity in both two-and three-dimensional models. Carlin S; Cunningham SH; Boyd M; McCluskey AG; Mairs RJ Cancer Gene Ther; 2000 Dec; 7(12):1529-36. PubMed ID: 11228531 [TBL] [Abstract][Full Text] [Related]
18. Combination therapy and noninvasive imaging with a dual therapeutic vector expressing MDR1 short hairpin RNA and a sodium iodide symporter. Park SY; Kwak W; Thapa N; Jung MY; Nam JO; So IS; Kim SY; Yoo J; Lee J; Kim IS J Nucl Med; 2008 Sep; 49(9):1480-8. PubMed ID: 18703598 [TBL] [Abstract][Full Text] [Related]
19. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Scholz IV; Cengic N; Baker CH; Harrington KJ; Maletz K; Bergert ER; Vile R; Göke B; Morris JC; Spitzweg C Gene Ther; 2005 Feb; 12(3):272-80. PubMed ID: 15510175 [TBL] [Abstract][Full Text] [Related]
20. Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy. Shen DH; Marsee DK; Schaap J; Yang W; Cho JY; Hinkle G; Nagaraja HN; Kloos RT; Barth RF; Jhiang SM Gene Ther; 2004 Jan; 11(2):161-9. PubMed ID: 14712300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]